Pharmacological modulation of this axis, using natural compounds and GLP-1 receptor agonists, has shown promise in treating metabolic syndrome [25], prompting interest in targeting SIRT1/AMPK signaling to manage multiple aspects of PCOS. The gene discussed is SIRT1; the disease is polycystic ovary syndrome.